American Journal of Obstetrics and Gynecology
SupplementInfant human immunodeficiency virus diagnosis in resource-limited settings: issues, technologies, and country experiences
Section snippets
Why test young infants?
Early HIV testing can help HIV-infected infants access treatment, provide reassurance for families of uninfected infants, and help PMTCT programs monitor their effectiveness. In settings with high HIV prevalence, a substantial proportion of infants who are ill may have HIV, and diagnosing symptomatic HIV cases on inpatient wards and in outpatient clinics is a critical priority for HIV treatment programs. Testing infants of known HIV-infected mothers through routine screening before they become
Barriers to testing infants
Early infant testing is becoming more available, but significant barriers still exist. Many clinicians believe that antibody tests have no value in infants; virologic tests are expensive and require sophisticated laboratory facilities. The expense of creating a laboratory with appropriate quality control and assurance to perform virologic testing is substantial, as are ongoing costs of test reagents. Laboratory technicians are in short supply in many resource-limited countries, and highly
Identifying infants for testing
The most obvious and accessible population requiring HIV testing is hospitalized and ill outpatient infants, who will have a high prevalence of HIV in any highly HIV-affected country. When available, PCR testing should be applied in hospital settings to confirm the HIV status of infants and direct their long-term medical management. In hospital settings in high-prevalence areas, routine HIV screening for all people with symptoms suggestive of HIV, quick access to HIV test results, and/or
HIV deoxyribonucleic acid (DNA) PCR
HIV DNA PCR is the standard method for virologic diagnosis of HIV in infants in the developed world. It has been used for many years, is the diagnostic test of choice recommended by the American Academy of Pediatrics and the WHO, and has excellent sensitivity and specificity.22, 23, 24 HIV infection can often be detected at birth, and essentially all perinatal infections are detectable by 4 weeks of age.25 Infections acquired postpartum (ie, through breast-feeding) can be detected by 4-6 weeks
Summary
Advances in technology and increases in funding for pediatric HIV have made early infant diagnosis of HIV infection more accessible than ever before. Despite this, most HIV-exposed infants in resource-limited settings in 2007 will not be tested for HIV. Although definitive virologic testing is the gold standard for infant diagnosis of HIV, it is important for programs without immediate capacity for virologic testing to recognize that the judicious use of basic clinical assessment and antibody
References (43)
- et al.
Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis
Lancet
(2004) - et al.
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial
Lancet
(2003) - et al.
Diagnosis of infection with human immunodeficiency virus type 1 by a DNA polymerase chain reaction assay among infants enrolled in the Women and Infants’ Transmission Study
J Pediatr
(1996) - et al.
Evaluation of a prototype Amplicor PCR assay for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults infected with HIV-1 subtypes A, C and D
J Clin Virol
(2000) - et al.
Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: comparison of the new COBAS TaqMan HIV-1 with three current HIV-RNA assays—LCx HIV RNA quantitative, VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor v1.5
J Virol Methods
(2006) - et al.
Use of population-specific infant mortality rates to inform policy decisions regarding HIV and infant feeding
J Nutr
(2005) - et al.
Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind, randomised, placebo-controlled trial
Lancet
(2004) - et al.
A review of clinical trials to prevent mother-to-child HIV-1 transmission in Africa and inform rational intervention strategies
AIDS
(2002) - et al.
Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected African children
Pediatr Infect Dis J
(2004) - et al.
Can clinical algorithms deliver an accurate diagnosis of HIV infection in infancy?
Bull World Health Organ
(2005)
Human immunodeficiency virus 1-specific IgA capture enzyme immunoassay for early diagnosis of human immunodeficiency virus 1 infection in infantsNYC Perinatal HIV Transmission Study Group
Pediatr Infect Dis J
Decay of transplacental human immunodeficiency virus type 1 antibodies in neonates and infants
J Infect Dis
Predicting perinatal human immunodeficiency virus infection by antibody patterns
Pediatr Infect Dis J
Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability
J Clin Microbiol
Psychosocial consequences of early diagnosis of HIV status in vertically exposed infants in Johannesburg, South Africa
Health Care Women Int
Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort
JAMA
Predictors of mortality in HIV-1 exposed uninfected post-neonatal infants at the Kenyatta National Hospital, Nairobi
East Afr Med J
Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia
AIDS
UNICEF/WHO technical consultation: improving access to appropriate paediatric ARV formulations
Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access
Routine and universal counseling and testing among hospitalized children at a University Teaching Hospital, Lusaka, Zambia
Cited by (0)
The findings and views expressed herein are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.